SOURCE: Vicor Technologies, Inc.

Vicor Technologies, Inc.

December 16, 2010 08:30 ET

Vicor Technologies Announces Exclusive Distribution Agreement for Its PD2i® Products in the People's Republic of China, Hong Kong, and Macau

BOCA RATON, FL--(Marketwire - December 16, 2010) - David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Guangzhou Jiyuan Biotech has become the exclusive distributor for the marketing and sale of the PD2i Analyzer™, PD2i CA (Cardiac Analyzer)™, and PD2i VS (Vital Sign)™ in the People's Republic of China (China), Hong Kong, and Macau. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events including cardiac death resulting from arrhythmia or pump failure, and autonomic nervous system dysfunction, and trauma victims in need of lifesaving intervention.

"We're extremely pleased to have Guangzhou Jiyuan Biotech representing our PD2i® technology. A medical device distributor in the People's Republic of China, Hong Kong, and Macau, Guangzhou Jiyuan Biotech was founded in 2002 and is a privately-held biotech company focused on the marketing, promotion, and distribution of medical devices, in vitro diagnostic reagents, and research products in the People's Republic of China. Guangzhou Jiyuan Biotech will obtain approval from the People's Republic of China's State Food and Drug Administration for the marketing of our products at its expense. We are confident that they will be successful in securing the necessary regulatory approvals for our products as quickly as possible," stated Mr. Fater.

"We are hopeful that this agreement is the first step toward significant international revenues as we continue to negotiate agreements with distributors in additional regions throughout the world," concluded Mr. Fater.

Additional information about Guangzhou Jiyuan Biotech may be found at
http://www.jy-biotech.com/EN/Index.asp.

About Vicor Technologies, Inc.
Vicor Technologies is a biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i®). The PD2i® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

Vicor currently has three products employing the PD2i® nonlinear algorithm. The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability; physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in multiple clinical trials, identifies patients at risk of sudden cardiac death.

Vicor anticipates additional applications employing the PD2i® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Disclaimer
The appearance in this release of name-brand institutions, such as the U.S. Army Institute for Surgical Research, does not constitute endorsement by these institutions of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to successfully complete the normal range study for PD2i® values; our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain FDA approval of our 510(k) submission to secure a marketing claim for the PD2i CA™(Cardiac Analyzer) for testing patients for cardiovascular disease and our ability to obtain marketing clearance from the FDA for the PD2i VS™ (Vital Sign) for military and civilian applications; our ability to obtain the necessary regulatory approvals to market in the People's Republic of China; our ability to develop additional applications for the PD2i® algorithm; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 10-26

Contact Information